Key result
Increased circulating VE-catherin independently predicted all-cause mortality and CHF-related death within 3 years in patients with ischemic chronic heart failure.
Why the study?
Does circulating VE-catherin predict mortality and rehospitalization in patients with ischemic symptomatic moderate-to-severe chronic heart failure?
Cohort (n=154)
Yes
Does circulating VE-catherin predict mortality and rehospitalization in patients with ischemic symptomatic moderate-to-severe chronic heart failure?
Answers are grounded in this paper and cite their sources.
Elevated circulating VE-catherin (>0.755 ng/ml) is a significant independent predictor of all-cause mortality, CHF-related death, and recurrent hospitalization in patients with ischemic moderate-to-severe CHF.
Aim: To evaluate the prognostic value of circulating VE-catherinfor cumulative survivalin patients with ischemic chronic heart failure (CHF).Methods: A total of 154 patients withischemic symptomatic moderate-to-severe CHF were enrolled in the study on discharge from the hospital. Observation period was up to 3 years. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used. Concentrations of VEcatherinfor cumulative survival cases due to advanced CHF were tested. Additionally, all-cause mortality, and CHFrelated death were examined.Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. Medians of circulating levels of VE-catherin in survived and died patient cohort were 0.63 ng/ml (95% confidence interval [CI] = 0.55-0.64 ng/ml) and 1.03 ng/ml (95% CI = 0.97-1.07 ng/ml) (P<0.001). ROC analysis has been shown that cutoff point of VE-catherin concentration for cumulative survival function was 0.755ng/ml. It has beenfound a significantly divergence of Kaplan-Meier survival curves in patients with high (>0.755 ng/ml) and low (<0.755 ng/ml) concentrations of VE-catherin. Circulating VE-catherin independently predicted all-cause mortality (OR = 1.27; 95% CI = 1.081.59; P = 0.002), CHF-related death (OR = 1.16; 95% CI 1.021.50; P < 0.001), and also CHF-related rehospitalisation (OR = 1.12; 95% CI = 1.07 1.25; P<0.001) within 3 years of observation period.Conclusion: Increased circulating VE-catherinassociates with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization due to CHF.J MEDICINE July 2015; 16 (2) : 73-78
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2015) conducted a cohort in Ischemic symptomatic moderate-to-severe chronic heart failure (n=154). Circulating VE-catherin vs. Low circulating VE-catherin (<0.755 ng/ml) was evaluated on All-cause mortality (OR 1.27, 95% CI 1.08-1.59, p=0.002). Increased circulating VE-catherin independently predicted all-cause mortality and CHF-related death within 3 years in patients with ischemic chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: